6 analysts have expressed a variety of opinions on Inari Medical NARI over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 0 | 3 | 0 | 0 |
| Last 30D | 2 | 0 | 2 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 1 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $67.5, a high estimate of $75.00, and a low estimate of $55.00. Highlighting a 7.53% decrease, the current average has fallen from the previous average price target of $73.00.
Investigating Analyst Ratings: An Elaborate Study
The analysis of recent analyst actions sheds light on the perception of Inari Medical by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mike Matson | Needham | Maintains | Buy | $72.00 | - |
| Richard Newitter | Truist Securities | Lowers | Hold | $61.00 | $63.00 |
| Adam Maeder | Piper Sandler | Lowers | Neutral | $55.00 | $85.00 |
| William Plovanic | Canaccord Genuity | Lowers | Buy | $75.00 | $79.00 |
| Mike Matson | Needham | Announces | Buy | $72.00 | - |
| Richard Newitter | Truist Securities | Raises | Hold | $70.00 | $65.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Inari Medical. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Inari Medical compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Inari Medical's stock. This comparison reveals trends in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Inari Medical's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Inari Medical analyst ratings.
All You Need to Know About Inari Medical
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism. The company generates revenue from the sale of ClotTriever and FlowTriever systems directly to hospitals located in the United States. Majority of revenue is generated from FlowTriever system.
Inari Medical: Financial Performance Dissected
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining Inari Medical's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 31.35% as of 30 September, 2023, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Inari Medical's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.5% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Inari Medical's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 0.71%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.59%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.07, Inari Medical adopts a prudent financial strategy, indicating a balanced approach to debt management.
What Are Analyst Ratings?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
